MAPK

[npj Precision Oncology] Complementary functional analyses of polyclonal EGFR-mutant cell pools showed a dose-dependent enrichment of BRAFV600E and a loss of EGFR inhibitor susceptibility.

[Frontiers in Cell and Developmental Biology] Scientists found that halofuginone inhibited the proliferation, induced G0/G1 phase arrest, and promoted apoptosis in lung cancer cells in a dose-dependent manner.

[Science Translational Medicine] Scientists identified and characterized resistance mechanisms to a FIRINOX chemotherapy regimen because it is the most aggressive regimen currently used clinically for patients with pancreatic ductal adenocarcinoma.

[British Journal of Pharmacology] Investigators developed C391, a potent proteinase-activated receptor-2 (PAR2) antagonist effective in blocking peptidomimetic- and trypsin-induced PAR2 signaling in vitro as well as reducing inflammatory PAR2-associated pain in vivo.

[Molecular Therapy-Nucleic Acids] RNA sequencing, qRT-PCR, and Western blot analysis were used to identify the aberrant expression and signaling of miR-148a-3p within cells, mice, and patients with Alzheimer’s disease (AD). Researchers implicated the miR-148a-3p/p35/PTEN pathway as an essential contributor to tau hyperphosphorylation and feed-forward regulation in AD.

[Biochemical Pharmacology] Luxeptinib inhibited the release of three cytokines from THP-1 monocytes and macrophages at concentrations of 0.1 µM and above.